CORT · Corcept Therapeutics Incorporat
$91.12
+3.37% last session
End-of-day data · updated 2026-07-29
Market cap
$10B
Enterprise value
$10B
Trailing P/E
261.6
Forward P/E
27.1
Dividend yield
—
Beta
0.46
Avg volume
1M
Employees
1K
2D change
3.37%
5D change
—
10D change
4.05%
30D change
7.17%
60D change
35.54%
MTD change
6.45%
YTD change
170.66%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — CORT
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-27
Latest call per bank · past 12 months
UBS
Buy$72.00
-21.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-27 | Wolfe Research | Downgrade | Peer Perform → Underperform | $0.00 → $50.00 |
| 2026-05-28 | Canaccord Genuity | Maintains | Buy | $110 → $135 |
| 2026-05-28 | HC Wainwright & Co. | Maintains | Buy | $75.00 → $95.00 |
| 2026-05-13 | UBS | Upgrade | Neutral → Buy | $44.00 → $72.00 |
| 2026-05-04 | HC Wainwright & Co. | Maintains | Buy | $60.00 → $75.00 |
| 2026-05-01 | Piper Sandler | Maintains | Overweight | $73.00 → $88.00 |
| 2026-03-26 | Canaccord Genuity | Maintains | Buy | $100 → $110 |
| 2026-03-26 | Wolfe Research | Upgrade | Underperform → Peer Perform | $0.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 60 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 17.9% above the 50-day MA ($79.88).
- Price vs 200-day MA: Trading 53.6% above the 200-day MA ($61.31).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.56) — short-term momentum is fading.
- 52-week range: Price is within 5% of the 52-week high ($96.66).
CORT Price Chart
Loading chart for CORT…
Fundamentals
About Corcept Therapeutics Incorporat
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$124B 8.2% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$73B -9.7% YTD
ARGX
argenx SE
$55B 3.7% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$39B -27.5% YTD
RVMD
Revolution Medicines, Inc.
$39B 130.8% YTD
RPRX
Royalty Pharma plc
$35B 56.7% YTD
ONC
BeOne Medicines Ltd.
$34B 8.8% YTD
INCY
Incyte Corporation
$26B 31.6% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.